Cargando…
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify fac...
Autores principales: | Nelke, Christopher, Stascheit, Frauke, Eckert, Carmen, Pawlitzki, Marc, Schroeter, Christina B., Huntemann, Niklas, Mergenthaler, Philipp, Arat, Ercan, Öztürk, Menekse, Foell, Dirk, Schreiber, Stefanie, Vielhaber, Stefan, Gassa, Asmae, Stetefeld, Henning, Schroeter, Michael, Berger, Benjamin, Totzeck, Andreas, Hagenacker, Tim, Meuth, Sven G., Meisel, Andreas, Wiendl, Heinz, Ruck, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005160/ https://www.ncbi.nlm.nih.gov/pubmed/35413850 http://dx.doi.org/10.1186/s12974-022-02448-4 |
Ejemplares similares
-
Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022) -
Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023) -
SOP myasthenic crisis
por: Stetefeld, Henning, et al.
Publicado: (2019) -
Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023) -
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis
por: Stascheit, Frauke, et al.
Publicado: (2022)